Insilico Medicine reported the AI‑driven discovery of a bifunctional PROTAC degrader targeting PKMYT1, a kinase implicated in cell‑cycle control and synthetic‑lethality vulnerabilities. Using its Chemistry42 platform, the company designed D16‑M1P2, which showed potency in CCNE1‑amplified and FBXW7‑mutant tumor models and produced tumor regression signals in xenografts, according to a Nature Communications paper. The team framed the work as precision targeting that pairs AI molecule generation with biomarker‑guided indications—patients with CCNE1 amplification or related genomic alterations could be prioritized. Insilico emphasized the platform speed and the ability to design nontraditional bifunctional molecules for hard oncology targets. The preclinical data validate AI‑first chemistry approaches for complex modalities such as PROTACs but will require translational work to confirm pharmacology, safety, and manufacturability before clinical entry.